Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy.
cardiomyopathy
exercise test
heart failure ◼ hospitalization
tafamidis
Journal
Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
30
6
2022
medline:
26
7
2022
entrez:
29
6
2022
Statut:
ppublish
Résumé
In patients with transthyretin amyloid cardiomyopathy, tafamidis was shown to slow the decline in 6-minute walking distance as compared with placebo. We aimed to define the impact of tafamidis and optimal background treatment on functional capacity as determined by cardiopulmonary exercise testing (CPET). Seventy-eight consecutive patients were enrolled in the study. They underwent CPET at baseline, and outcome defined as death or heart failure hospitalization was obtained for a time period of up to 30 months. Fifty-four patients completed a follow-up CPET at 9±3 months (range, 4-16 months). Improvement in peak VO Baseline peak VO Our findings demonstrate that baseline peak VO
Sections du résumé
BACKGROUND
In patients with transthyretin amyloid cardiomyopathy, tafamidis was shown to slow the decline in 6-minute walking distance as compared with placebo. We aimed to define the impact of tafamidis and optimal background treatment on functional capacity as determined by cardiopulmonary exercise testing (CPET).
METHODS
Seventy-eight consecutive patients were enrolled in the study. They underwent CPET at baseline, and outcome defined as death or heart failure hospitalization was obtained for a time period of up to 30 months. Fifty-four patients completed a follow-up CPET at 9±3 months (range, 4-16 months). Improvement in peak VO
RESULTS
Baseline peak VO
CONCLUSIONS
Our findings demonstrate that baseline peak VO
Identifiants
pubmed: 35766028
doi: 10.1161/CIRCHEARTFAILURE.121.008381
doi:
Substances chimiques
Benzoxazoles
0
Prealbumin
0
Carbon Dioxide
142M471B3J
tafamidis
8FG9H9D31J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e008381Commentaires et corrections
Type : CommentIn